Targeting HSV-1 virions for specific binding to epidermal growth factor receptor-vIII-bearing tumor cells
Authors:
Open Access
- 28 May 2010
- journal article
- research article
- Published by Springer Nature in Cancer Gene Therapy
- Vol. 17 (9) , 655-663
Abstract
Oncolytic herpes simplex virus (HSV) vectors have been used in early phase human clinical trials as a therapy for recurrent malignant glioblastoma. This treatment proved safe but limited improvements in patient survival were observed. The potency of these vectors might be enhanced by targeting vector infectivity to tumor cells. Glioma tumors often express a mutant form (vIII) of the epidermal growth factor receptor (EGFR) resulting in the presence of a novel epitope on the cell surface. This epitope is specifically recognized by a single-chain antibody designated MR1-1. HSV-1 infection involves initial binding to heparan sulfate (HS) on the cell surface mediated primarily by the viral envelope, glycoprotein C (gC). Here we joined the MR1-1 single-chain antibody (scFv) to the gC sequence deleted for the HS-binding domain as a means of targeting viral attachment to EGFRvIII on glial tumor cells. Virions bearing MR1-1-modified gC had fivefold increased infectivity for EGFRvIII-bearing human glioma U87 cells compared to mutant receptor-deficient cells. Further, MR1-1/EGFRvIII-mediated infection was more efficient for EGFRvIII-positive cells than was wild-type virus for either positive or negative cells. Sustained infection of EGFRvIII+ glioma cells by MR1-1-modified gC-bearing oncolytic virus, as compared to wild-type gC oncolytic virus, was also shown in subcutaneous tumors in vivo using firefly luciferase as a reporter of infection. These data show that HSV tropism can be manipulated so that virions recognize a cell-specific binding site with increased infectivity for the target cell. The retargeting of HSV infection to tumor cells should enhance vector specificity, tumor cell killing and vector safety.Keywords
This publication has 51 references indexed in Scilit:
- Epidermal Growth Factor Receptor (EGFR)–Retargeted Measles Virus Strains Effectively Target EGFR- or EGFRvIII Expressing GliomasMolecular Therapy, 2007
- The status of gene therapy for brain tumorsExpert Opinion on Biological Therapy, 2007
- Epidermal Growth Factor Receptor–Mediated Signal Transduction in the Development and Therapy of GliomasClinical Cancer Research, 2006
- Specific targeted binding of herpes simplex virus type 1 to hepatocytes via the human hepatitis B virus preS1 peptideGene Therapy, 2004
- HSV-1 Virions Engineered for Specific Binding to Cell Surface ReceptorsMolecular Therapy, 2004
- Targeting HSV amplicon vectorsMethods, 2004
- In Vivo Imaging of HIV Protease Activity in Amplicon Vector-transduced GliomasCancer Research, 2004
- Real-time imaging of TRAIL-induced apoptosis of glioma tumors in vivoOncogene, 2003
- ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour propertiesGene Therapy, 2003
- Oncolytic herpes simplex virus vectors for cancer virotherapyCancer Gene Therapy, 2002